Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | PLG | P00747 | 1/20 | 0.54 |
| ▸ | PLAT | P00750 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | GABRP | O00591 | 2/20 | 0.48 |
| ▸ | GABRD | O14764 | 2/20 | 0.48 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.48 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.48 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.48 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.48 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.48 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.48 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.48 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.48 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.48 |
| ▸ | GABRE | P78334 | 2/20 | 0.48 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.48 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.48 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.48 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL382975 | 1.00 | LMNA (0.54) | LMNAPLGPLATTSHRGABRP | |
| SCHEMBL29265359 | 1.00 | LMNA (0.54) | LMNAPLGPLATTSHRGABRP | |
| SCHEMBL218064 | 1.00 | LMNA (0.54) | LMNAPLGPLATTSHRGABRP | |
| Hydrochloric Acid SCHEMBL3363679 | 0.97 | LMNA (0.52) | LMNAPLGPLATTSHRGABRP | |
| SCHEMBL20581837 | 0.97 | LMNA (0.52) | LMNAPLGPLATTSHRGABRP | |
| Hydrochloric Acid SCHEMBL384984 | 0.97 | LMNA (0.52) | LMNAPLGPLATTSHRGABRP | |
| Hydrochloric Acid SCHEMBL420116 | 0.97 | LMNA (0.52) | LMNAPLGPLATTSHRGABRP | |
| SCHEMBL15401674 | 0.97 | LMNA (0.52) | LMNAPLGPLATTSHRGABRP | |
| SCHEMBL15401713 | 0.97 | LMNA (0.52) | LMNAPLGPLATTSHRGABRP | |
| Methane SCHEMBL28827281 | 0.97 | LMNA (0.52) | LMNAPLGPLATTSHRGABRP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 751 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116120213-A | Synthesis method of trans-4- (tert-butoxycarbonylamino) cyclohexane carboxylic acid | 重庆医药高等专科学校 | 2023-05-16 | — | — | CN | claimed |
| CN-116082192-A | Preparation method of trans-4- (tert-butoxycarbonylamino) cyclohexane carboxylic acid | 重庆医药高等专科学校 | 2023-05-09 | — | — | CN | claimed |
| CN-113402428-B | Preparation method of trans-4- (tert-butoxycarbonylamino) cyclohexanecarboxylic acid and intermediate thereof | 重庆医药高等专科学校 | 2023-03-03 | — | — | CN | claimed |
| CN-112125565-B | Concrete corrosion and rust inhibitor and preparation method thereof | 中国石油天然气集团公司 | 2022-05-31 | — | — | CN | claimed |
| CN-113402428-A | Preparation method of trans-4- (tert-butoxycarbonylamino) cyclohexanecarboxylic acid and intermediate thereof | 重庆医药高等专科学校 | 2021-09-17 | — | — | CN | claimed |
| US-20210238183-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | SUMITOMO PHARMA AMERICA, INC. | 2021-08-05 | — | — | US | claimed |
| CN-112125565-A | Concrete corrosion and rust inhibitor and preparation method thereof | 中国石油天然气集团公司 | 2020-12-25 | — | — | CN | claimed |
| EP-2516009-B1 | SUBSTITUTED ISOQUINOLINONES AND QUINAZOLINONES | NOVARTIS AG (CH) | 2014-09-24 | — | — | EP | claimed |
| US-8357654-B2 | Multimeric CD40 ligands, method for preparing same and use thereof for preparing drugs | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2013-01-22 | — | — | US | claimed |
| US-20100183642-A1 | NOVEL MULTIMERIC CD40 LIGANDS, METHOD FOR PREPARING SAME AND USE THEREOF FOR PREPARING DRUGS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2010-07-22 | — | — | US | claimed |
| US-20100136034-A1 | NOVEL MULTIMERIC MOLECULES, A PROCESS FOR PREPARING THE SAME AND THE USE THEREOF FOR MANUFACTURING MEDICINAL DRUGS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2010-06-03 | — | — | US | claimed |
| EP-1828240-B1 | NOVEL MULTIMERIC CD40 LIGANDS, METHOD FOR PREPARING SAME AND USE THEREOF FOR PREPARING DRUGS | CENTRE NAT RECH SCIENT (FR) | 2009-07-29 | — | — | EP | claimed |
| US-5679640-A | BINDING TO MAJOR HISTOCOMPATIBILITY COMPLEX (MHC) E.G. HLA-DR'S, TO INHIBIT HLA-DR RESTRICTED T CELL ACTIVATION; AUTOIMMUNE DISEASES; ANTIARTHRITIC AGENTS | CYTEL CORPORATION (US) | 1997-10-21 | — | — | US | claimed |
| JP-57122062-A | — | — | None | — | — | JP | disclosed |
| CN-122059854-A | Guanidino cyclohexane derivative and preparation method and application thereof | 安徽益普克医药科技发展有限公司 | 2026-05-19 | — | — | CN | disclosed |
| EP-4709720-A1 | INHIBITORS AND DEGRADERS OF PIP4K PROTEIN | Larkspur Biosciences, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| US-4309429-A | NEUROLEPTIC, ANTIEMETIC | KEFALAS A/S (DK) | 1982-01-05 | — | — | US | disclosed |
| US-4285956-A | NEUROLEPTIC AND ANTICHOLENERGIC AGENTS; PSYCHOLOGICAL DISORDERS INCLUDING SCHIZOPHRENIA; ANTIEMETIC AGENTS | KEFALAS A/S (DK) | 1981-08-25 | — | — | US | disclosed |
| US-4275209-A | NEUROLEPTIC AND ANTIEMETIC ACTIVITY FOR TREATMENT OF PSYCHOLOGICAL DISORDERS | KEFALAS A/S (DK) | 1981-06-23 | — | — | US | disclosed |
| EP-0005607-A1 | Xanthone and thioxanthone derivatives, their preparation and pharmaceutical compositions containing them | KEFALAS A/S (DK) | 1979-11-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100183642-A1 | NOVEL MULTIMERIC CD40 LIGANDS, METHOD FOR PREPARING SAME AND USE THEREOF FOR PREPARING DRUGS | CD40, CD40LG, TNFSF10 | LMNA 1693/4885PLG 2292/4885PLAT 1182/4885 |
| US-20210238183-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | PIM1, PIM2, PIM3 | LMNA 2351/4885PLG 2785/4885PLAT 1809/4885 |
| US-20100136034-A1 | NOVEL MULTIMERIC MOLECULES, A PROCESS FOR PREPARING THE SAME AND THE USE THEREOF FOR MANUFACTURING MEDICINAL DRUGS | TNFRSF1A, TNFRSF9, CD40 | LMNA 3111/4885PLG 2786/4885PLAT 2302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.